NeoStem Reports Positive Stem Cell Industry Research Trends From The Journal of the American Medical Association and Third Annual Stem Cell Summit

Multiple Clinical Applications for Blood-Derived Stem Cells and Strong Industry Outlook Support NeoStem's Business Model

NEW YORK, February 28, 2008 /PRNewswire-FirstCall/ -- NeoStem, Inc. , which is pioneering the pre-disease collection, processing and long-term storage of adult stem cells for future medical need, today reported on several positive research conclusions and industry trends presented in The Journal of the American Medical Association and at the recent Third Annual Stem Cell Summit hosted by RRY Publications LLC, in New York City.

An article in the February 27th volume of The Journal of the American Medical Association entitled, "Clinical Applications of Blood-Derived and Marrow-Derived Stem Cells for Nonmalignant Diseases" studied a broad array of clinical studies conducted between January 1997 and December 2007 and concluded that there was evidence that stem cells harvested from blood or bone marrow did appear to provide disease-ameliorating effects in certain auto- immune diseases and cardiovascular disorders. The article also highlighted that the vast majority of human stem cell trials have focused on clinical applications for hematopoietic and/or mesenchymal stem cells, both of which may be obtained from peripheral blood, bone marrow, or umbilical cord blood and placenta.

The National Institutes of Health lists more than 1,500 clinical trials currently underway in the US investigating adult stem cell use as potential breakthrough therapies for a myriad of diseases, including, cancer, diabetes, heart and vascular disease, and autoimmune disorders such as lupus, multiple sclerosis and arthritis. More than 500 of these are for autologous use, meaning the stem cells come from your own body for your own use.

Adult stem cells are already the standard of care in treating over 40 diseases including bone marrow cancers and other diseases such as radiation sickness or bone marrow deficiencies from chemotherapy.

At the recent Stem Cell Summit in New York, renowned analyst Robin Young, President of RRY Publications, estimated that approximately 11,000 patients in the US have received stem cells as part of their conventional treatment in the past two years. He also noted that in the United States alone, there are over 34 million people available for eventual stem cell therapeutic treatment in 15 medical markets including heart repair, diabetes, fractures, cartilage repair, spinal fusion and Crohn's disease, among others. Young projects the US stem cell therapy market to generate well over $8.5 billion in revenue by 2017 and estimates that stem cells will be used therapeutically in as many as 1.973 million annual procedures.

NeoStem's ability to provide adult stem cell collection and banking services to the general population for their future medical use places the Company in a unique position to benefit from the rapidly growing need for autologous, blood-derived stem cells. In addition, the Company's proprietary Very Small Embryonic Like Stem Cells (VSELs), identified in adult bone marrow, is expected to serve as the basis for NeoStem's entry into the therapeutic market place.

Robin Smith, MD MBA, NeoStem's Chairman and Chief Executive Officer commented: "As clinical understanding of the benefits of blood-derived stem cells grows, so does the potential value of a personal supply of one's own stem cells. With our expanding nationwide network of collection centers, we are enabling people to donate and store their own (autologous) stem cells when they are young and healthy for their personal use in times of future medical need."

About NeoStem, Inc.

NeoStem is managing a growing nationwide network of adult stem cell collection centers, enabling people to donate and store their own (autologous) stem cells when they are young and healthy for their personal use in times of future medical need. The Company has also recently entered the research and development and therapeutic arenas, through the acquisition of a worldwide exclusive license to an early-stage technology to identify and isolate rare stem cells from adult human bone marrow, called VSELs (very small embryonic- like stem cells), which have been shown to have several physical characteristics that are generally found in embryonic stem cells.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements concerning the ability of NeoStem, Inc. ("the Company") to develop the adult stem cell business, to develop the VSEL technology, the future of regenerative medicine and the role of adult stem cells and VSELs in that future, the future use of adult stem cells and VSELs as a treatment option and the potential revenue growth of the Company's business. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. The Company's ability to enter the adult stem cell arena, its success in such arena and future operating results are dependent upon many factors, including but not limited to (i) the Company's ability to obtain sufficient capital or a strategic business arrangements to fund its expansion plans; (ii) the Company's ability to build the management and human resources and infrastructure necessary to support the growth of its business; (iii) competitive factors and developments beyond the Company's control; (iv) scientific and medical developments beyond the Company's control; (v) the Company's inability to obtain appropriate state licenses or any other adverse effect or limitations caused by government regulation of the business; (vi) whether any of the Company's current or future patent applications result in issued patents; and (vii) other risk factors discussed in the Company's periodic filings with the Securities and Exchange Commission.

     Contact:

     NeoStem, Inc.

     Robin Smith, Chief Executive Officer

     T: 212-584-4180

     E: 

     www.neostem.com

rsmith@neostem.com

CONTACT: Robin Smith, Chief Executive Officer of NeoStem, Inc.,+1-212-584-4180, rsmith@neostem.com

Web site: http://www.neostem.com/

Ticker Symbol: (AMEX:NBS)

Terms and conditions of use apply
Copyright © 2008 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Posted: February 2008

View comments

Hide
(web4)